Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. Annual Report - Your Investor Snapshot

Dive into the essential insights from Rapport Therapeutics' (Nasdaq: RAPP) performance and outlook for the fiscal year ended December 31, 2023. We've distilled the key information to provide a clear and accessible overview for every investor.

1. Business Overview

Rapport Therapeutics, a Boston, MA-based clinical-stage biotechnology company, develops precision medicines for central nervous system (CNS) disorders. The company's core strategy utilizes its proprietary RAP technology platform, designed to precisely target specific brain pathways. This approach aims to address the underlying causes of neurological conditions, striving for improved effectiveness and fewer side effects. Rapport's lead product candidate, RAP-201, targets drug-resistant epilepsy, while RAP-302 is advancing for neuropathic pain.

2. Financial Performance

As a clinical-stage company, Rapport Therapeutics currently generates no revenue. For the fiscal year ended December 31, 2023, the company reported a net loss of $85.5 million. This loss primarily stemmed from substantial research and development (R&D) expenses, which totaled $72.1 million. General and administrative expenses amounted to $13.4 million. These figures reflect the company's significant investment in advancing its product pipeline.

As of March 15, 2024, Rapport had approximately 47.8 million shares of common stock outstanding. The public float, representing shares available to regular investors, was valued at approximately $275.8 million. These numbers offer a snapshot of the company's market capitalization and shareholder base.

3. Risk Factors

Investing in Rapport Therapeutics carries significant risks, typical for a clinical-stage biotech company:

• Clinical Trial Success: The success of RAP-201 and RAP-302 is crucial. Future clinical trials (e.g., Phase 2 for RAP-201) may not yield positive results, or product candidates may not prove safe and effective.
• Regulatory Approval: Obtaining FDA and other international regulatory approvals is a lengthy, complex, and uncertain process. Delays or rejections would severely impact the company.
• RAP Technology Platform Validation: The RAP platform's long-term success depends on its ability to consistently generate viable product candidates that succeed in clinical development.
• Funding Needs: Rapport requires substantial additional capital to complete clinical development, pursue regulatory approvals, and potentially commercialize products. Failure to raise this capital on favorable terms could significantly hinder operations.
• Intellectual Property Protection: Protecting its proprietary technology and product candidates through patents and other means is crucial. Challenges to its intellectual property (IP) or inability to license necessary third-party IP could impact its competitive edge.
• Competition: The CNS market is crowded with established pharmaceutical companies and other biotech firms. Rapport's product candidates may not compete effectively.

4. Management's Discussion and Analysis (MD&A) Highlights

Management highlighted significant operational progress in 2023, marked by key clinical and intellectual property achievements. A critical milestone was the successful completion of the Phase 1 trial for RAP-201, their lead epilepsy candidate, which demonstrated a favorable safety profile and preliminary signs of efficacy. The advancement of RAP-302 into IND-enabling studies furthered pipeline progression. The company also strengthened its intellectual property portfolio by securing additional patents related to its RAP platform and specific product candidates.

These advancements, however, led to increased R&D expenses, contributing to the net loss. Management views this as a necessary investment in pipeline progression. Minor clinical trial delays due to vendor availability and intense competition within the CNS therapeutic space posed challenges.

Leadership remained stable throughout the year, with no significant changes to executive management or the Board of Directors, reinforcing a consistent strategic focus. Management monitors the dynamic CNS therapeutic market, noting trends toward precision medicines targeting specific disease mechanisms and an increasing focus on rare neurological disorders. They acknowledge potential expedited regulatory pathways for therapies addressing unmet medical needs, while recognizing the stringent regulatory landscape. The company's strategy capitalizes on these trends through its differentiated precision approach and continuous monitoring of evolving guidelines for CNS drug development and intellectual property protection.

5. Financial Health

Rapport Therapeutics maintains a solid financial position. As of December 31, 2023, the company reported cash, cash equivalents, and marketable securities totaling $210.3 million. It currently holds no long-term debt.

Based on current operational plans and projected expenditures, management estimates existing cash resources will fund operations into late 2025. This provides a financial runway for key clinical milestones but indicates a future need for additional capital.

6. Future Outlook

Rapport Therapeutics' primary focus for 2024 and beyond includes:

• Initiating Phase 2 Clinical Trial for RAP-201: Expected to commence mid-2024, this is a critical step for their lead candidate.
• Advancing RAP-302: Progressing RAP-302 through IND-enabling studies, aiming to file an Investigational New Drug (IND) application in early 2025.
• Platform Expansion: Leveraging the RAP technology platform to identify and develop new product candidates for other CNS indications.
• Strategic Partnerships: Exploring potential collaborations or partnerships to accelerate development or commercialization efforts.

7. Competitive Position

Rapport Therapeutics aims to differentiate itself through its precision approach, using the RAP technology platform to focus on specific neural circuits. Key competitors in the epilepsy and neuropathic pain markets include established players like Pfizer and Johnson & Johnson, as well as newer biotech firms developing novel CNS therapies.

Rapport believes its selective modulation approach could offer improved efficacy and reduced side effects compared to existing broad-acting treatments. However, they face the challenge of proving this differentiation in larger clinical trials and gaining market acceptance against well-entrenched therapies.